Akebia Therapeutics (AKBA), a biopharmaceutical company focused on kidney disease, Thursday has priced its underwritten public offering of 25 million common stock shares at $2.00 per share, aiming to raise $50 million before expenses.
The company has also granted underwriters a 30-day option to purchase an additional 3.75 million shares. The offering is expected to close on March 21, 2025, subject to customary conditions.
The shares are offered under a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024. The offering is being conducted solely through a prospectus and prospectus supplement available on the SEC's website or from the underwriting firms.
Thursday, AKBA closed at $2.04, marking a 28.17% decline, and remained unchanged in after-hours trading on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.